Intermune's orphan Esbriet escapes reference pricing in Germany
This article was originally published in Scrip
Executive Summary
Intermune's idiopathic pulmonary fibrosis treatment Esbriet (pirfenidone) offers patients "unquantifiable" added therapeutic benefit that will later be defined in light of clinical practice, according to Germany's federal joint committee, the G-BA. The decision trumps an earlier benefit assessment declaring that the orphan drug offered no extra benefit and therefore spares it from reference pricing.